SARS-Co, V-2 is a single-stranded positive-stranded RNA virus (6). Its genome encodes four structural proteins: spike protein (S), small protein (E), matrix protein (M) and nucleocapsid protein (N) (79). Spike protein is a type I fusion protein that forms trimers on the surface of infection particles. It consists of two subunits, S1 and S2: S1 mainly contains receptor binding domain (RBD), which is responsible for acknowledging cell receptors and S2 is accountable for membrane blend.
For that reason, the RBD of spike protein identifies the infectivity of infection and its spread in the host (10, 13, 14). Although ballya bio established by some researches use antibodies against SARS-Co, V-2 N protein (15). Most of vaccines and antibody rehabs under advancement are directed against SARS-Co, V-2 spike protein RBD because the protein is the main antigen that causes a protective immune action (1619).
7 meaning that the bandwidth of SARS-Co, V-2 is much higher than that of SARS-Co, V (R0: 0. 853) (20). The world urgently needs an effective and safe vaccine, which will play a decisive function in worldwide epidemic control. According to the draft prospect vaccines published by the WHO on August 27, 2020, there are 143 vaccines worldwide in preclinical trials, 33 vaccines have gotten in clinical trials, of which 8 vaccines have actually gotten in clinical phase III trials.
Vaccines under research study include widely used traditional vaccines, particularly inactivated or attenuated vaccines, genetically engineered recombinant subunit vaccines, adenovirus vector vaccines, recombinant infection vector vaccines, and new vaccines that have not been authorized for comparable vaccines, generally consisting of ribose Nucleic acid (RNA) vaccines and deoxyribonucleic acid (DNA) vaccines. Amongst these vaccines, spike protein-based vaccines occupy a certain number.
It is especially important that vaccination is helpful to the prevention and control of the epidemic. A study (21) discovered that Ig, G titers continue for more than 4 months after the start of symptoms, which implies that long-term resistance to COVID-19 might be observed or vaccinated. Therefore, it is required to establish a gold immunochromatographic strip for rapid detection of SARS-Co, V-2 spike protein in order to find the antigen material of spike protein to keep track of vaccine quality.